2-[(3R,5S)-1-[(dimethylamino)methyl]-3,5-dimethylcyclohexyl]acetic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[(3R,5S)-1-[(dimethylamino)methyl]-3,5-dimethylcyclohexyl]acetic acid
• 化学式: C₁₃H₂₅NO₂
• 分子量: 227.34
• InChiKey: HDSRMJUMTZMCES-QYJAPNMZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1157000A1

  公开（公告）日：2001-11-28
• [EN] BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY<br/>[FR] INHIBITEURS D'AMINOTRANSFERASE ACIDES AMINES-DEPENDANTE A CHAINE RAMIFIEE, ET LEUR UTILISATION DANS LE CADRE DU TRAITEMENT DE LA RETINOPATHIE DIABETIQUE
  申请人：WARNER LAMBERT CO

  公开号：WO2001042191A1

  公开（公告）日：2001-06-14

  The present invention is directed to a method for the prophylactic and therapeutic treatment of diabetic retinopathy. The method involves the administration of an inhibitor of formulae (I), (II) and (III) of the branch chain amino acid-dependent aminotransferase (BCAT) pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the retina for diabetic retinopathy prophylactically or therapeutically. The present invention is also directed to several novel inhibitors of formula (IV) of the BCAT pathway. In formulae (I-IV), n, m, X and R1-R13 have the meanings given in the description.